Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's Keytruda Fails in Late-Stage Breast Cancer Study

by Zacks Equity Research

Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.

Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

by Zacks Equity Research

The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

by Zacks Equity Research

Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

by Zacks Equity Research

Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

What's in Store for Axsome (AXSM) This Earnings Season?

by Zacks Equity Research

On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

by Zacks Equity Research

Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

by Kinjel Shah

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Can Allergan (AGN) Beat Earnings Estimates Again in Q1?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1

by Zacks Equity Research

Glaxo beats both earnings and sales estimates in the first quarter of 2019.

Pfizer (PFE) Beats on Q1 Earnings & Sales, Raises EPS View

by Zacks Equity Research

Pfizer (PFE) beat estimates for first-quarter earnings and sales and raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales.

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

What's in Store for BioSpecifics (BSTC) This Earnings Season?

by Zacks Equity Research

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is expected to provide updates on the pipeline, when it reports first-quarter 2019 results on May 2.

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.

Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.

Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

Exelixis (EXEL) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

Lannett (LCI) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches

Kinjel Shah headshot

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

by Kinjel Shah

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.

Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.